MetaCap

Opus Genetics (IRD) vs PepGen (PEPG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Opus Genetics (IRD) has outperformed PepGen (PEPG) over the past year, gaining 108.9% versus a loss of 32.0%. Opus Genetics is the larger company by market cap ($385.7 million vs $356.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRD+108.90%PEPG-32.01%
+232%+71%-90%
Nov 21, 20251 yearNov 20, 2026
IRD+82.19%PEPG-70.67%
+196%+45%-105%
May 2, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRD versus PEPG key metrics
MetricIRDPEPG
Share price$3.99$3.78
Market cap$385.65M$356.31M
1-day change-2.21%-3.82%
YTD return+98.51%-41.94%
1-year return+108.90%-32.01%
5-year return-8.28%—
EPS (TTM)$-1.48$-0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.20M—
Revenue growth (YoY)+29.15%—
Net income (latest FY)$-49.59M$-89.66M
Operating margin-271.90%—
Net margin-349.33%—
52-week high$7.07$7.80
52-week low$1.88$1.31
Distance from 52-week high-43.56%-51.54%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+249.37%+263.76%
Average volume2.56M3.26M
Shares outstanding96.65M94.26M
Employees2753
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRD has outperformed PEPG by 140.9 percentage points over the past year.

About Opus Genetics

IRD stock →

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees

About PepGen

PEPG stock →

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees

IRD vs PEPG FAQ

Which is bigger, Opus Genetics or PepGen?

Opus Genetics (IRD) is larger, with a market capitalization of $385.65M compared with $356.31M for PepGen (PEPG).

Which stock has performed better over the past year, IRD or PEPG?

IRD returned +108.90% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.

Are Opus Genetics and PepGen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons